Filing Flows › Gyre Therapeutics (GYRE) › Guidance history
Gyre Therapeutics (GYRE) guidance history: what it guided and what it reported
Gyre Therapeutics gave guidance in 2 earnings releases on file since Aug 7, 2026.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $100M–$111M (Aug 7, 2026) → reaffirmed $100M–$111M (Nov 5, 2026) | — | to be reported | — |
The latest quarter
Gyre Therapeutics, Q3 2026: revenue $32.9M (+0.7% year over year), operating margin -4.6%, net loss $2.5M, operating cash flow −$4.0M. The chart follows the revenue to costs, profit and cash.
Questions
Does Gyre Therapeutics beat its guidance?
Gyre Therapeutics gave guidance in 2 earnings releases on file since Aug 7, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.